Results 101 to 110 of about 681,792 (231)
Liver Organoids: From Disease Modelling to Regenerative Medicine
Cell Proliferation, EarlyView.Liver organoids provide a versatile platform for disease modelling and drug discovery, leveraging stem cells and engineering techniques. They bridge research and clinical applications, offering significant potential for advancing precision medicine and regenerative therapies for liver diseases.
Tiepeng Wang +5 more
wiley +1 more source
The Journal of Physiology, EarlyView.Abstract figure legend CAF origins and plasticity give rise to distinct phenotypes with immunosuppressive functions in colorectal cancer and multiple myeloma. These distinct CAF phenotypes contribute to immunosuppressive tumour microenvironments through ECM remodelling, cytokine signalling and immune regulation.
Hui Mo +4 more
wiley +1 more source
The Journal of Physiology, EarlyView.Abstract figure legend Downregulation of mitotically associated long non‐coding RNA (MANCR) disturbs transcriptome and proteome in endothelial cells, possibly leading to endothelial and vascular dysfunction in preeclampsia. Abstract Preeclampsia (PE) is a hypertensive disorder during pregnancy, which is characterized by a wide spectrum of endothelial ...
Si‐Yan Zhang, Chi Zhou, Jing Zheng
wiley +1 more source
FGFR a promising druggable target in cancer: Molecular biology and new drugs
, 2017 Introduction The Fibroblast Growth Factor Receptor (FGFR) family consists of Tyrosine Kinase Receptors (TKR) involved in several biological functions.
Shahanavaj Khan +28 more
core +1 more source
International Journal of Cancer, Volume 160, Issue 1, Page 201-215, 1 January 2027.ABSTRACT Biliary tract cancers (BTCs) are aggressive malignancies associated with a poor prognosis. Although molecular profiling is recommended to guide therapeutic decision‐making, real‐practice data on the prevalence and prognostic significance of genomic alterations in European BTC cohorts remain limited.
Jorine Arnouts +14 more
wiley +1 more source
Journal of Clinical and Translational ScienceOBJECTIVES/GOALS: There are gain-of-function genomic alterations in FGFR genes that guide personalized treatment in some patients with cholangiocarcinoma (10%) and bladder cancer (30%) who can benefit from targeted therapies.
Leah Stein +9 more
doaj +1 more source
Change‐of‐function fibroblast growth factor receptor 3 mutations causing skeletal dysplasias
Journal of Cell Communication and Signaling, Volume 20, Issue 4, December 2026.We show that the ligands FGF1 and FGF2 elicit differential fibroblast growth factor receptor 3 (FGFR3) signaling responses and that the FGFR3 G380R and A391E mutations reshape these signaling outputs. Thus, pathogenic FGFR3 mutations found in skeletal dysplasia do not simply enhance signaling strength and should be reclassified from “gain‐of‐function ...
Tanaya Roy +4 more
wiley +1 more source
International Journal of Cancer, Volume 159, Issue 11, Page 2766-2777, 1 December 2026.ABSTRACT The recommended adjuvant chemotherapy (adj‐ChT) regimen for resected biliary tract cancers (BTC) is capecitabine (Cape); yet, the recommendation is based on limited evidence. Although varied adj‐ChTs have been employed in practice, robust real‐world data is scarce. We conducted a national, multicenter, hospital‐based registry study to evaluate
Erman Akkus +60 more
wiley +1 more source
Clinical development and management of adverse events associated with FGFR inhibitors. [PDF]
Cell Rep Med, 2023 Subbiah V, Verstovsek S.
europepmc +1 more source
The Journal of Pathology, Volume 270, Issue 4, Page 507-520, December 2026.Abstract Fibroblast growth factor receptor 1 (FGFR1) amplification, a significant cancer alteration with both prognostic and therapeutic relevance, lacks a standardized definition. The relationship between FGFR1 copy number (CN) variations and tumour microenvironment (TME) characteristics also remains poorly understood.
Yike Gao +6 more
wiley +1 more source